Sciformix Rated Among the ‘Top 20 Most Promising Pharma and Life Sciences Solution Providers’
News Apr 25, 2016
The companies were selected by a panel of experts based on select criteria for outstanding performance in areas such as industry solutions, innovation, client satisfaction and overall company performance.
The 20 Most Promising “Pharma & Life Sciences Solutions Providers – 2016” recognition was created by Silicon India, with a vision to help pharmaceutical and life sciences companies find the best partner and highlight the outstanding service providers in this domain. The life sciences industry has been witnessing significant global growth, creating unprecedented opportunities for outsourcing activities to niche and specialized providers and utilizing optimized processes in areas such as drug safety, regulatory affairs and clinical operations. These domain-intensive processes require strong subject matter expertise which is where SPOs (Scientific Process Organizations) such as Sciformix contribute. By using analytics and processes as enablers, Sciformix provides value through its industry focus, domain competency, depth of subject matter expertise and commitment to quality.
A distinguished panel of the industry’s top most CIOs, CEOs, VCs and other experts including Silicon India’s Editorial Board scrutinized the list of companies on different business criteria. According to the judges, ‘The distinguished offering in the space of SPO, with a dedication to provide scientific knowledge-based services to foster efficiency and quality, is what makes Sciformix unique from others. It helps clients reduce their regulatory and business risks by bringing experience that bears positive results and enhances client value.’
This acknowledgment demonstrates how Sciformix has addressed the market and its clients’ needs by providing “best-in-class” scientific services to life science organizations. These services span the entire product life cycle, from pre-clinical to clinical to post-marketing activities. On the announcement of the recognition, President and CEO of Sciformix, Manish Soman, commented ‘We are deeply honored to be included in this list, and humbled to be in the company of such innovative and accomplished solution providers.”
He added “Our mission is to be the preferred partner for global life sciences companies. We want to continue providing high quality scientific knowledge-based expertise that delivers quality results and improves efficiencies across the entire product lifecycle. Our overarching objective has always been to improve the quality of patient treatment worldwide. This recognition is a testament that we are in fact living our mission”.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018